ArticleMethodsX2022
Deep learning program to predict protein functions based on sequence information.
Article in MethodsX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 21 citations in OpenAlex.
- Classification of driver and passenger mutations in different cancer types using deep neural networks.Bioinformatics advances · 2026Article
- A multimodal model for protein function prediction.Scientific reports · 2025Article
- Prediction of inhibitory peptides against E.coli with desired MIC value.Scientific reports · 2025Article
- Deep learning methods for protein function prediction.Proteomics · 2025Review
- MAN-C: A masked autoencoder neural cryptography based encryption scheme for CT scan images.MethodsX · 2024Article
- Diffusion models in bioinformatics and computational biology.Nature reviews bioengineering · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep learning technologies have been adopted to predict the functions of newly identified proteins in silico. However, most current models are not suitable for poorly characterized proteins because they require diverse information on target proteins. We designed a binary classification deep learning program requiring only sequence information. This program was named 'FUTUSA' (function teller using sequence alone). It applied sequence segmentation during the sequence feature extraction process, by a convolution neural network, to train the regional sequence patterns and their relationship. This segmentation process improved the predictive performance by 49% than the full-length process. Compared with a baseline method, our approach achieved higher performance in predicting oxidoreductase activity. In addition, FUTUSA also showed dramatic performance in predicting acetyltransferase and demethylase activities. Next, we tested the possibility that FUTUSA can predict the functional consequence of point mutation. After trained for monooxygenase activity, FUTUSA successfully predicted the impact of point mutations on phenylalanine hydroxylase, which is responsible for an inherited metabolic disease PKU. This deep-learning program can be used as the first-step tool for characterizing newly identified or poorly studied proteins.•We proposed new deep learning program to predict protein functions in silico that requires nothing more than the protein sequence information.•Due to application of sequence segmentation, the efficiency of prediction is improved.•This method makes prediction of the clinical impact of mutations or polymorphisms possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.